As per the USFDA#39;s Orange Book contains that data of all approved drugs in US, the patents of Imbruvica will start expiry only from 2026, some patents are valid all the way till 2033-2034.
Subscribe to:
Post Comments (Atom)
-
Huawei faces international scrutiny over its ties with the Chinese government and suspicion that Beijing could use Huawei#39;s technology f...
-
In July, HCL Technologies had announced a Rs 4,000 crore buyback programme for FY19 at a price of Rs 1,100 per equity share.
No comments:
Post a Comment